CSE PREV
LAST 0.025
CHANGE 0.000
OTC PRVCF
FSE 18H
CSE: PREV
LAST: 0.025
CHANGE: 0.000
OTC: PRVCF
FSE: 18H
Download as PDF  

PreveCeutical Announces Certain Warrants Expiring on June 29, 2020

Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), is informing its shareholders that 134,151,350 common share purchase warrants (the “Warrants”) issued in connection with the Company’s June 29, 2018, non-brokered private placement, including 6,301,600 finder’s warrants, will expire on June 29, 2020.  Each Warrant currently entitles the holder thereof to purchase one common share of the Company at an exercise price of $0.10 per share. 

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. 

PreveCeutical aims to be a leader in preventive health sciences.  The Company’s current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical™ peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook

On behalf of the Board of Directors of PreveCeutical

Stephen Van Deventer, Chairman and Chief Executive Officer

For further information, please contact:

Stephen Van Deventer at telephone:  +1 604 306 9669

Or, Investor Relations ir@preveceutical.com           

Forward-Looking Statements:

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995.  All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans and expectations regarding the future, including, without limitation, the anticipated business plans and timing of future business activities of the Company. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time.  These reports and the Company’s Canadian continuous disclosure filings are available at www.sedar.com.

Readers are cautioned not to put undue reliance on forward-looking statements.  These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements.

Sign up for the latest news and updates